IBRX Stock: Price, Earnings History and SEC Filings
ImmunityBio, Inc. (IBRX) last traded at $8.29, down 5.15% on the latest session and down 12.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.08 against an analyst estimate of $-0.09, a beat of 11.1%.
$8.29 -5.15%
1 month-12.18%
52-week high$12.43
52-week low$1.95
Volume8.91M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IBRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.08 | $-0.09 | +11.11% |
| Mar 2026 | May 7, 2026 | $-0.09 | $-0.08 | -12.50% |
| Dec 2025 | Feb 23, 2026 | $-0.06 | $-0.08 | +25.00% |
| Sep 2025 | Nov 4, 2025 | $-0.07 | $-0.10 | +30.00% |
IBRX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IBRX
SEC filing data is not available right now. You can search for IBRX on SEC EDGAR.
IBRX news
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Oct 30, 2026 · stocktwits.com
- Insmed (INSM) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Oct 29, 2026 · finance.yahoo.com
- IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover WaveOct 27, 2026 · stocktwits.com
- Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?Oct 22, 2026 · finance.yahoo.com
- ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing NearsOct 21, 2026 · stocktwits.com
- ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerOct 21, 2026 · finance.yahoo.com
- ANKTIVA Label Expansion Could Change The Case For ImmunityBio StockOct 19, 2026 · finance.yahoo.com
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a US-listed public company on Nasdaq.